Novel molecular markers in well-differentiated thyroid cancers

Area of Science:

• Endocrinology
• Oncology
• Cytopathology

Background:

• Conventional cytopathology accurately distinguishes benign from malignant thyroid nodules but often yields indeterminate results.
• Indeterminate thyroid cytology leads to numerous unnecessary diagnostic thyroidectomies.
• Improving diagnostic accuracy for indeterminate thyroid lesions is crucial to reduce patient morbidity and healthcare costs.

Purpose of the Study:

• To review the role of molecular markers in enhancing the diagnostic accuracy of thyroid fine-needle aspiration cytology.
• To assess the potential of novel molecular markers in differentiating thyroid tumor subtypes and providing prognostic information.
• To evaluate the clinical utility of molecular markers as adjuncts to conventional cytopathology for thyroid lesions.

Main Methods:

• Review of existing literature on molecular markers in thyroid cancer diagnosis.
• Analysis of studies assessing markers like galectin-3, thyroid peroxidase, PTTG, PBF, BRAF, and MUC1.
• Evaluation of sensitivity, specificity, and prognostic value of identified molecular markers.

Main Results:

• Established markers like galectin-3 and thyroid peroxidase demonstrate high accuracy in differentiating malignant from benign thyroid lesions.
• Emerging gene markers (PTTG, PBF, BRAF, MUC1) show potential for distinguishing tumor subtypes and offering prognostic insights.
• While promising, larger, controlled studies are required before routine clinical integration of these novel markers.

Conclusions:

• Molecular markers represent a significant advancement in translational thyroid cancer research.
• These markers hold the potential to improve the diagnostic accuracy of fine-needle aspiration cytology, especially for indeterminate thyroid nodules.
• Future integration of molecular markers with conventional histology could optimize thyroid nodule diagnosis and patient management.